PloS one

NLK is a novel therapeutic target for PTEN deficient tumour cells.

PloS one

Mendes-Pereira AM, Lord CJ, Ashworth A

Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity.

PloS one

Hegde GV, de la Cruz C, Eastham-Anderson J, Zheng Y, Sweet-Cordero EA, Jackson EL

Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity.

PloS one

Hegde GV, de la Cruz C, Eastham-Anderson J, Zheng Y, Sweet-Cordero EA, Jackson EL

Overexpression of calcium-permeable glutamate receptors in glioblastoma derived brain tumor initiating cells.

PloS one

Oh MC, Kim JM, Safaee M, Kaur G, Sun MZ, Kaur R, Celli A, Mauro TM, Parsa AT

Pages